Africa50 is a pan-African infrastructure investor and asset manager established to help close Africa’s infrastructure-financing gap. It develops investment-ready projects, mobilises public and private capital, and invests equity and quasi-equity alongside strategic partners. Africa50 focuses on projects and businesses that combine development impact with appropriate risk-adjusted returns. Its shareholders are predominantly African institutions, including African governments, African central banks, African pension funds and development finance institutions. Its investors include the African Development Bank and South Africa’s Public Investment Corporation, the continent’s largest pension fund manager. Africa50 invested in AHN in 2023.
The U.S. International Development Finance Corporation (DFC) is the international investment arm of the U.S. Government. Established in 2019, DFC mobilises private capital to support economic development and strategic priorities in emerging markets. It provides debt and equity financing, guarantees, political-risk insurance, project-development support and investment funds across sectors including healthcare, energy, infrastructure, agriculture, financial services and technology. DFC’s portfolio spans more than 100 countries and is designed to generate development impact while maintaining rigorous environmental, social and governance standards. DFC invested in AHN in 2021.
AfricInvest is a leading pan-African investment platform active across private equity, venture capital, private credit and listed equities. Founded in the early 1990s, the firm invests in growing African businesses and supports them with strategic, financial, technical and commercial expertise. AfricInvest has more than 100 professionals across 11 offices and has invested in more than 200 companies across 35 African countries. Its sector experience includes healthcare, financial services, agribusiness, consumer and retail, and education. AfricInvest invested in AHN in 2023 through its Transform Health Fund.
Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company established in 1964. The company develops and manufactures orphan drugs and generic medicines, with particular expertise in childhood cancers and hepatobiliary and pancreatic cancers. Its generic-drug activities emphasise product design intended to reduce medication accidents. Ohara’s wider ambition is to provide total healthcare solutions spanning prevention, diagnosis, treatment and aftercare, including through partnerships in Asia and Africa. Ohara invested in AHN in 2023.